News

Medical Dialogues1d
Largest phase 3 trial of novel treatment for hypertension shows promising results
The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, ...
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and ...
Clinical Trials Arena3d
Mineralys reports outcomes from trial of lorundrostat for hypertension
Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...
MyChesCo on MSN4d
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, ...
MyChesCo on MSN6d
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN ...